- Trials with a EudraCT protocol (67)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
67 result(s) found for: Focusing.
Displaying page 1 of 4.
EudraCT Number: 2010-019423-61 | Sponsor Protocol Number: GENRAS | Start Date*: 2010-10-28 |
Sponsor Name:Medizinische Universität Wien,Univ.Klinik f.Psychiatrie und Psychotherapie | ||
Full Title: GENRAS (GENetics of Response to Agomelatine vs. EScitalopram) | ||
Medical condition: depressive disorder | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-003139-50 | Sponsor Protocol Number: Maxillo1 | Start Date*: Information not available in EudraCT |
Sponsor Name:University of Bergen, Faculty of medicin and dentistry, Dep. of Clinical Dentistry | ||
Full Title: International, multicenter phase II uncontrolled prospective clinical trial: Jaw bone reconstruction using a combination of biomaterial and autologous mesenchymal stem cells prior to dental impla... | ||
Medical condition: Men and women aged 18 years or more requiring jaw bone reconstruction prior to dental implant placement based on clinical and radiological examinations (CBCT Cone beam CT imaging). Areas suitable ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2005-002996-34 | Sponsor Protocol Number: PK 2005 xx | Start Date*: 2006-04-27 |
Sponsor Name:University Hospitals of Leicester NHS Trust | ||
Full Title: Pharmacokinetics of actinomycin D in children with cancer | ||
Medical condition: Any children's cancer where this drug is administered as part of the treatment regimen | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-004112-19 | Sponsor Protocol Number: POLARIS2013-001 | Start Date*: 2018-07-10 | |||||||||||
Sponsor Name:Polaris Pharmaceuticals, Inc. | |||||||||||||
Full Title: Phase 1-2 Study of ADI-PEG 20 plus FOLFOX in Subjects with Advanced Gastrointestinal Malignancies Focusing on Hepatocellular Carcinoma | |||||||||||||
Medical condition: Advanced hepatocellular carcinoma (HCC)in the third line or later setting | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001381-26 | Sponsor Protocol Number: CER-001-CLIN-010 | Start Date*: 2015-07-22 |
Sponsor Name:CERENIS THERAPEUTICS SA | ||
Full Title: A PHASE II MULTI-CENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FOCUSING TRIAL OF CER-001 IN SUBJECTS WITH ACUTE CORONARY SYNDROME | ||
Medical condition: Acute Coronary Syndrome (ACS) with significant plaque volume | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Completed) NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2008-000461-28 | Sponsor Protocol Number: Resubmission A | Start Date*: 2008-06-10 | ||||||||||||||||
Sponsor Name:Karolinska institutet | ||||||||||||||||||
Full Title: Effect of exercise or metformin on nocturnal blood pressure and other risk factors for cardiovascular heart disease among obese adolescents | ||||||||||||||||||
Medical condition: The aim is to, among obese adolescents study impact of exercise or metformin therapy on nocturnal blood pressure and related cardiovascular disease risk factors (e.g. insulin sensitivity, IMT, LVM,... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-003684-54 | Sponsor Protocol Number: ACLS | Start Date*: 2014-03-27 |
Sponsor Name:Academic Medical Center Amsterdam | ||
Full Title: Analgesic efficacy of saphenous nerve blockade for outpatient knee anterior cruciate ligament surgery | ||
Medical condition: Mid thigh saphenous nerve block with levobupivacain, as compared to femoral nerve block, in patients undergoing anterior cruciate ligament surgery | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-001436-35 | Sponsor Protocol Number: COFITAGE2016 | Start Date*: 2017-01-06 |
Sponsor Name:Service of Neurology, CHU Liege | ||
Full Title: How sleep and circadian rhythmicity promote cognitive fitness and protect against cognitive decline in the elderly population | ||
Medical condition: Healthy middle aged (50 - 70 y.o.) individual with and without preclinical Alzheimer's disease defined by biomarkers | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2015-003050-41 | Sponsor Protocol Number: HJE-PHARMA-001 | Start Date*: 2015-11-10 | |||||||||||
Sponsor Name:Rigshospitalet | |||||||||||||
Full Title: Efficacy of GLP-1 agonists and restrictive vs. liberal FiO2 in patients undergoing coronary artery bypass grafting or aortic valve replacement – a 2-by-2 factorial designed, randomized clinical study | |||||||||||||
Medical condition: We investigate the efficacy of commercially available GLP-1 analog for reducing organ damage in patients undergoing heart surgery (i.e. coronary artery bypass grafting and/or aortic valve replaceme... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-007190-20 | Sponsor Protocol Number: D144AC00003 | Start Date*: 2009-12-14 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: An International, Multicenter, Double-blind, Randomized, Placebo-controlled, Phase IV Study of the Safety and Efficacy of Lithium versus Placebo as an add on to SEROQUEL XR™ (Quetiapine Fumarate) i... | |||||||||||||
Medical condition: Acut mania in subjects with bipolar I disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002649-39 | Sponsor Protocol Number: WC28038 | Start Date*: 2012-11-15 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A SINGLE-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE II STUDY TO ASSESS THE EFFICACY OF ALEGLITAZAR ON INSULIN SENSITIVITY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2D) WHO ARE IN... | |||||||||||||
Medical condition: Type II Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004087-30 | Sponsor Protocol Number: 1007612/30.04.2010 | Start Date*: 2011-08-25 | |||||||||||
Sponsor Name:Tartu University Department of Sports Medicine and Rehabilitation | |||||||||||||
Full Title: Effect of 12 weeks rehabilitation (aspect of neuromuscular physical therapy) in middle-aged patients in post-atroscopic period | |||||||||||||
Medical condition: Cartilage Lesion of the Knee Joint | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005490-30 | Sponsor Protocol Number: PP21/14 | Start Date*: 2022-04-28 |
Sponsor Name:Hospital Universitario Son Llàtzer | ||
Full Title: EFFECTIVENESS OF TREATMENT WITH ANTISEPTICS VERSUS TOPICAL ANTIBIOTICS IN MILD IMPETIGO IN PEDIATRIC PATIENTS | ||
Medical condition: Impetigo is a bacterial infection of very common skin in the pediatric population. In the usual clinical practice, the treatment of this infection has been based on topical antibiotics. The widespr... | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-001391-42 | Sponsor Protocol Number: Speed-Covid | Start Date*: 2021-05-12 |
Sponsor Name:Medical University of Graz | ||
Full Title: Characterisation of the effects of Spermidine on the immune response to Covid-19 vaccine in older people - a feasibility study | ||
Medical condition: For assessing the immune cell function after COVID-19 vaccine, peripheral blood mononuclear cells (PBMC) will be separated after blood sampling and measurements as follows will be done: • FACS anal... | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2019-003857-27 | Sponsor Protocol Number: LUPSA | Start Date*: 2020-01-23 |
Sponsor Name:Radboudumc | ||
Full Title: 177Lu-PSMA Radioligand Therapy for advanced salivary gland cancer, a phase II pilot study. | ||
Medical condition: Salivary gland cancer. More specifically two subtypes: adenoid cystic carcinoma and salivary duct carcinoma. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005427-36 | Sponsor Protocol Number: NL75654.078.20 | Start Date*: 2021-05-26 |
Sponsor Name:Erasmus MC Cancer Center [...] | ||
Full Title: A multicenter, open label non-randomized phase I/II dose escalation study with extension cohort to determine the safety, tolerability and immune modulating effects of the therapeutic LRPAP1 synthet... | ||
Medical condition: non small cell lung cancer (NSCLC) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-004691-22 | Sponsor Protocol Number: RCT-004 | Start Date*: 2017-11-21 | |||||||||||
Sponsor Name:Rechon Life Science AB | |||||||||||||
Full Title: A Randomised, Open, Parallel-group Phase III Biosimilarity Study to Assess the Long-term Safety, Focusing on Immunogenicity, of Rechon Insulin Human Soluble in Type 1 Diabetic Patients. | |||||||||||||
Medical condition: Type 1 Diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000106-19 | Sponsor Protocol Number: GO29689 | Start Date*: 2015-12-10 | |||||||||||
Sponsor Name:Genentech, Inc | |||||||||||||
Full Title: A PHASE II, OPEN-LABEL, RANDOMIZED STUDY OF GDC-0810 VERSUS FULVESTRANT IN POSTMENOPAUSAL WOMEN WITH ADVANCED OR METASTATIC ER+/HER2- BREAST CANCER RESISTANT TO AROMATASE INHIBITOR THERAPY | |||||||||||||
Medical condition: Advanced or Metastatic ER+/HER2- Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-002825-29 | Sponsor Protocol Number: EORTC 40051 | Start Date*: 2006-10-06 |
Sponsor Name:European Organisation for Research and Treatment of Cancer | ||
Full Title: Randomized phase II trial evaluating the feasibility and tolerance of the combination of FOLFOX with cetuximab and the combination of FOLFOX with cetuximab and bevacizumab as perioperative treatmen... | ||
Medical condition: resectable liver metastases of colorectal cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) DE (Completed) SE (Completed) AT (Completed) GB (Completed) FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-001511-73 | Sponsor Protocol Number: WA40404 | Start Date*: 2019-12-23 |
Sponsor Name:F. Hoffmann-La Roche Ltd | ||
Full Title: A PHASE IIIb MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN ADULTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS | ||
Medical condition: | ||
Disease: | ||
Population Age: | Gender: | |
Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) PT (Trial now transitioned) IE (Completed) DE (Completed) BG (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) BE (Trial now transitioned) HU (Completed) HR (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
